Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 CNS MRI study of gadoquatrane vs macrocyclic GBCAs
jRCT2011230023Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of gadoquatrane in central nervous system conditions (CNSD) (2 arms), sponsored by Bayer. Primary endpoints: Visualization parameter: contrast enhancement, Visualization parameter: lesion delineation and 1 more. Started Aug 2023; status: completed.
02
Drugs
gadoquatrane
03
Conditions
central nervous system conditions (CNSD)
Beyond the preview
Go deeper on jRCT2011230023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230023.